Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Publication Date: May 9, 2022
Last Updated: May 11, 2022
Diagnosis of IC/BPS
The basic assessment should include a careful history, physical examination, and laboratory examination to document symptoms and signs that characterize IC/BPS and exclude other disorders that could be the cause of the patient's symptoms. (Clinical Principle, )
322859
Baseline voiding symptoms and pain levels should be obtained in order to measure subsequent treatment effects. (Clinical Principle, )
322859
Cystoscopy and/or urodynamics should be considered when the diagnosis is in doubt; these tests are not necessary for making the diagnosis in uncomplicated presentations. (Expert Opinion, )
322859
Cystoscopy should be performed in patients for whom Hunner lesions are suspected. (Expert Opinion, )
322859
Management Approach to IC/BPS
Treatment decisions should be made after shared decision-making, with the patient informed of the risks, potential benefits, and alternatives. Except for patients with Hunner lesions, initial treatment should typically be nonsurgical. (Expert Opinion, )
322859
Efficacy of treatment should be periodically reassessed, and ineffective treatments should be stopped. (Clinical Principle, )
322859
Multimodal pain management approaches (e.g., pharmacological, stress management, manual therapy if available) should be initiated. Pain management should be continually assessed for effectiveness because of its importance to quality of life. If pain management is inadequate, then consideration should be given to a multidisciplinary approach and the patient referred appropriately. (Clinical Principle, )
322859
The IC/BPS diagnosis should be reconsidered if no improvement occurs after multiple treatment approaches. (Clinical Principle, )
322859
Behavioral/Non-pharmacologic Treatments
Patients should be educated about normal bladder function, what is known and not known about IC/BPS, the benefits versus risks/burdens of the available treatment alternatives, the fact that no single treatment has been found effective for the majority of patients, and the fact that acceptable symptom control may require trials of multiple therapeutic options (including combination therapy) before it is achieved. (Clinical Principle, )
322859
Self-care practices and behavioral modifications that can improve symptoms should be discussed and implemented as feasible. (Clinical Principle, )
322859
Patients should be encouraged to implement stress management practices to improve coping techniques and manage stress-induced symptom exacerbations. (Clinical Principle, )
322859
Appropriate manual physical therapy techniques (e.g., maneuvers that resolve pelvic, abdominal and/or hip muscular trigger points, lengthen muscle contractures, and release painful scars and other connective tissue restrictions), if appropriately trained clinicians are available, should be offered to patients who present with pelvic floor tenderness. Pelvic floor strengthening exercises (e.g., Kegel exercises) should be avoided. (Standard, A)
322859
Clinicians may prescribe pharmacologic pain management agents (e.g., urinary analgesics, acetaminophen, NSAIDs, opioid/non-opioid medications) after counseling patients on the risks and benefits. Pharmacological pain management principles for IC/BPS should be similar to those for management of other chronic pain conditions. (Clinical Principle, )
322859
Oral Medications
The following oral medications may be administered (listed in alphabetical order; no hierarchy is implied):
Amitriptyline: Amitriptyline has been shown to be superior to placebo to improve symptoms of IC/BPS; however, AEs are common and, although not lifethreatening, have substantial potential to compromise QoL (e.g., sedation, drowsiness, nausea). Available data suggest that beginning at low doses (e.g., 10 mg) and titrating gradually to 75-100 mg if tolerated is an acceptable dosing regimen. (Option, B)
322859
Cimetidine: Cimetidine has been reported to have clinically significant improvement of IC/BPS symptoms, pain, and nocturia with no AEs reported. (Option, B)
322859
Hydroxyzine: Oral hydroxyzine has been shown to result in clinically significant improvement compared to placebo.10 Some studies indicate that patients who report clinically significant improvement have systemic allergies; this patient population may be more likely to respond to hydroxyzine. AEs were common and generally not serious (e.g., short-term sedation, weakness). (Option, C)
322859
Pentosan polysulfate: Pentosan polysulfate (PPS) is the only FDA-approved oral agent for the treatment of IC/BPS and is by far the most-studied oral medication in use for IC/BPS. Results on the effectiveness of PPS have been contradictory; some trials report no differences in symptom improvement,12 10 while others show that PPS patients improved compared to those on placebo. Overall, it is the opinion of the Panel that the benefits and risks of PPS should be discussed with the patient before initiating or continuing treatment. (Option, B)
322859
Clinicians should counsel patients who are considering pentosan polysulfate on the potential risk for macular damage and vision-related injuries. (Clinical Principle, )
322859
Oral cyclosporine A may be offered to patients with Hunner lesions refractory to fulguration and/or triamcinolone. (Option, C)
322859
Intravesical Instillations
DMSO, heparin, and/or lidocaine may be administered as intravesical treatments (listed in alphabetical order; no hierarchy is implied).
DMSO: DMSO instillation has been shown to be efficacious in improving urodynamic and voiding parameters as compared to placebo, to bacillus Calmette-Guerin (BCG), and in observational studies. DMSO is rapidly absorbed into the bladder wall and longer periods of holding are associated with significant pain, therefore if DMSO is used, then the panel suggests limiting instillation dwell time to 15-20 minutes. DMSO is often administered as a part of a "cocktail" that may include heparin, hydrocortisone, sodium bicarbonate, a local steroid, a lidocaine preparation, bupivacaine, and/or triamcinolone. If a clinician chooses to administer a "cocktail" preparation, then he or she should be aware that DMSO potentially enhances absorption of other substances, creating the possibility for toxicity from drugs such as lidocaine. (Option, C)
322859
Heparin: Observational studies of intravesical heparin and clinical trials of patients randomized heparin in combination with alkalized lidocaine report clinically significant improvement in symptom relief compared to patients who were given placebo. (Option, C)
322859
Lidocaine: Lidocaine has been shown to significantly improve symptoms in the short-term (i.e., less than two weeks) compared to placebo. Alkalinization increases urothelial penetration of lidocaine and therefore is expected to improve efficacy, but it also can increase systemic absorption and potential toxicity. No published studies have directly compared lidocaine with and without alkalinization. Patients who are given lidocaine in combination with heparin or PPS32 have been show to exhibit relief of symptoms and a significant reduction of bladder pain and urgency compared to lidocaine alone. (Option, B)
322859
Procedures
Cystoscopy under anesthesia with short-duration, low-pressure hydrodistension may be undertaken as a treatment option. (Option, C)
322859
If Hunner lesions are present, then fulguration (with electrocautery) and/or injection of triamcinolone should be performed. (Conditional, C)
322859
Intradetrusor onabotulinumtoxin A may be administered if other treatments have not provided adequate improvement in symptoms and quality of life. Patients must be willing to accept the possibility that intermittent self-catheterization may be necessary. (Option, C)
322859
A trial of neuromodulation may be performed if other treatments have not provided adequate symptom control and quality of life improvement. If a trial of nerve stimulation is successful, then the permanent neurostimulation device may be implanted. (Option, C)
322859
Major Surgery
Major surgery (substitution cystoplasty, urinary diversion with or without cystectomy) may be undertaken in carefully selected patients with bladder-centric symptoms, or in the rare instance when there is an end-stage small fibrotic bladder, for whom all other therapies have failed to provide adequate symptom control and quality of life improvement. (Option, C)
322859
Treatments That Should Not Be Offered
Long-term oral antibiotic administration should not be offered. (Standard, B)
322859
Intravesical instillation of bacillus Calmette-Guerin should not be offered outside of investigational study settings. (Standard, B)
322859
High-pressure, long-duration hydrodistension should not be offered. (Conditional, C)
322859
Systemic (oral) long-term glucocorticoid administration should not be offered. (Conditional, C)
322859
Recommendation Grading
Overview
Title
Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome
Authoring Organization
American Urological Association
Publication Month/Year
May 9, 2022
Last Updated Month/Year
September 3, 2024
Supplemental Implementation Tools
Document Type
Guideline
Country of Publication
US
Document Objectives
This guideline provides direction to clinicians and patients regarding how to recognize interstitial cystitis/bladder pain syndrome (IC/BPS), conduct a valid diagnostic process, and approach treatment with the goals of maximizing symptom control and patient quality of life while minimizing adverse events and patient burden.
IC/BPS is a heterogeneous clinical syndrome. Even though patients present with similar symptoms of bladder/pelvic pain and pressure/discomfort associated with urinary frequency and strong urge to urinate, there are subgroups or phenotypes within IC/BPS. Except for patients with Hunner lesions, initial treatment should typically be nonsurgical. Concurrent, multi-modal therapies may be offered.
Target Patient Population
Patients with IC/BPS
Target Provider Population
Urologists and other providers caring for patients with IC/BPS
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Diagnosis, Assessment and screening, Treatment, Management
Diseases/Conditions (MeSH)
D018856 - Cystitis, Interstitial, D003556 - Cystitis
Keywords
Interstitial Cystitis, bladder pain, IC/BPS
Source Citation
Clemens JQ, Erickson DR, Varela NP, Lai HH. Diagnosis and Treatment of Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2022 Jul;208(1):34-42. doi: 10.1097/JU.0000000000002756. Epub 2022 May 10. PMID: 35536143.
Methodology
Number of Source Documents
271
Literature Search Start Date
December 31, 1982
Literature Search End Date
December 31, 2020